114 related articles for article (PubMed ID: 11563840)
1. Effect of hypoxia on cellular adhesion to vitronectin and fibronectin.
Lash GE; Fitzpatrick TE; Graham CH
Biochem Biophys Res Commun; 2001 Sep; 287(3):622-9. PubMed ID: 11563840
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.
Xue W; Mizukami I; Todd RF; Petty HR
Cancer Res; 1997 May; 57(9):1682-9. PubMed ID: 9135008
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
5. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
6. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
7. The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts.
Monaghan E; Gueorguiev V; Wilkins-Port C; McKeown-Longo PJ
J Biol Chem; 2004 Jan; 279(2):1400-7. PubMed ID: 14602715
[TBL] [Abstract][Full Text] [Related]
8. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
9. Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding.
Ramani VC; Haun RS
Pancreas; 2008 Nov; 37(4):399-404. PubMed ID: 18953252
[TBL] [Abstract][Full Text] [Related]
10. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
12. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Hapke S; Kessler H; Arroyo de Prada N; Benge A; Schmitt M; Lengyel E; Reuning U
J Biol Chem; 2001 Jul; 276(28):26340-8. PubMed ID: 11331280
[TBL] [Abstract][Full Text] [Related]
13. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
14. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.
Ria R; Vacca A; Ribatti D; Di Raimondo F; Merchionne F; Dammacco F
Haematologica; 2002 Aug; 87(8):836-45. PubMed ID: 12161360
[TBL] [Abstract][Full Text] [Related]
15. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors.
Wilcox-Adelman SA; Wilkins-Port CE; McKeown-Longo PJ
Cell Adhes Commun; 2000; 7(6):477-90. PubMed ID: 11051458
[TBL] [Abstract][Full Text] [Related]
16. Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.
Wei Y; Czekay RP; Robillard L; Kugler MC; Zhang F; Kim KK; Xiong JP; Humphries MJ; Chapman HA
J Cell Biol; 2005 Jan; 168(3):501-11. PubMed ID: 15684035
[TBL] [Abstract][Full Text] [Related]
17. alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells.
Vacca A; Ria R; Presta M; Ribatti D; Iurlaro M; Merchionne F; Tanghetti E; Dammacco F
Exp Hematol; 2001 Aug; 29(8):993-1003. PubMed ID: 11495705
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Adachi Y; Lakka SS; Chandrasekar N; Yanamandra N; Gondi CS; Mohanam S; Dinh DH; Olivero WC; Gujrati M; Tamiya T; Ohmoto T; Kouraklis G; Aggarwal B; Rao JS
J Biol Chem; 2001 Dec; 276(50):47171-7. PubMed ID: 11572856
[TBL] [Abstract][Full Text] [Related]
19. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.
Colman RW; Pixley RA; Najamunnisa S; Yan W; Wang J; Mazar A; McCrae KR
J Clin Invest; 1997 Sep; 100(6):1481-7. PubMed ID: 9294114
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
